Kornimate/medical-research-clean huggingface dataset:
pediatric postoperative analgesia with quadratus lumborum block(qlb) and dexamethasone as an adjuvant to bupivacaine.

Conditions: Post Operative Pain; Quadratus Lumborum Block; Pediatric; Abdominal Surgery

Summary: studying the post-operative analgesic effect of dexamethasone as an adjuvant to bupivacaine giving intravenously and locally with ultrasound guided quadratus lumborum block(qlb) in pediatrics undergoing abdominal surgeries

after obtaining written informed consent from parents or guardians of all patients, 90 patients (6-12 years old) scheduled for abdominal surgeries operations will be included. patients will be randomly allocated into three groups, 30 patients in each group. randomization will be based on computer-generated codes maintained in sequentially numbered opaque envelopes. anesthetic technique: anesthesia will be induced with sevoflurane plus fentanyl (0.5µg/kg) and tracheal intubation will be facilitated with rocuronium (0.4 mg/kg). anesthesia will be maintained with sevoflurane (will be adjusted according to a line autoregressive index (aai)) and rocuronium (0.1 mg/kg/dose will be given on the basis of train-of-four neuromuscular monitoring). ecg, noninvasive blood pressure, heart rate, temperature, oxygen saturation, and exhaled co2 (end tidal co2) will be continuously monitored during the procedure. • after induction of anesthesia and before skin incision, a qlb will be performed in all patients in the three groups. the procedure will be done under ultrasound guidance using curved array transducer 5-2mhz (sonosite ultrasound system). echogenic needle, sono plex stim cannula (pajunk) 22 gauge and 60 mm length will be used. with the patient in the supine position, the site of the ultrasound and needle entry will be sterilized. the qlb block will be performed by anterior approach. the linear probe will be attached in the area of the triangle of petit in transverse orientation in lateral abdomen in between the iliac crest and the costal margin, near the posterior axillary line. the muscle planes will be identified until visualizing the quadratus lumborum muscle, at the same plane as the psoas major muscle and the erector spinae. the needle tip is placed at the anterolateral border of the ql at its junction of ql with transversalis fascia outside the anterior layer of the thoracolumbar fascia (tlf) and fascia transversalis, and the local anesthetic will be injected. anesthesia will be discontinued when the wound dressing applied, and muscle relaxant will be reversed using (50ug/kg) of neostigmine and atropine (0.02mg/kg) and extubating of the patient will be done. the patient will be transferred to the postoperative care unit (pocu).

Eligibility criteria:
inclusion criteria: * pediatric patients(6-12 years) * asa physical status i,ii * abdominal surgery exclusion criteria: * parents refusal or legal guardian's refusal * allergy to bupivacaine or dexamethasone * contraindications to regional techniques * failed qlb * infection on site of procedure

Keywords: quadratus lumborum block in pediatrics dexamethasone
a study of treatment alk(+) systemic anaplastic large cell lymphoma with crizotinib

Conditions: Systemic Anaplastic Large-Cell Lymphoma

Summary: the purpose of this study is to determine the efficacy and safety of crizotinib combined with chop chemotherapy for patients with alk(+) systemic anaplastic large cell lymphoma.

alk(+) systemic anaplastic large cell lymphoma patients are treated with crizotinib when they receive chop chemotherapy. crizotinib 250mg twice a day is administrated from day 1 of chemotherapy to 18 weeks. standard chop chemotherapy (cyclophosphamide, 750mg per square meter of body-surface area,d1, vincristine, 1.4mg per square meter of body-surface area, maximal dose is 2mg d1, doxorubicin, 50mg per square meter of body-surface area d1, plus prednison, 100 mg d1-5) every 3 weeks for up to six cycles.

Eligibility criteria:
inclusion criteria: * primary alk(+) systemic anaplastic large cell lymphoma histologically confirmed by biopsy without therapy * ecog 0-2 * more than 1 measurable lesions with major axis \>1.5cm and minor axis\>1.0cm * estimated survival \>/3months * age 18-65 years * women of childbearing age should have a negative pregnancy test; men and women who need to agree to use effective contraception during the period of treatment and the following 1 years * signature of informed consent exclusion criteria: * age \<\\ 18years * without alk(+) systemic anaplastic large cell lymphoma histologically confirmed by biopsy * without measurable lesions * being treated by other drugs in other clinical trials * pregnant or lactating women, who are not willing to take contraceptive measures during the study period, or are not willing to use effective contraceptive measures during the period of treatment and the following 1 years * hepatic insufficiency: serum total bilirubin, alt more than 2 times higher than normal * renal insufficiency: more than 2 times higher than that of normal serum creatinine * blood screening period: wbc \< 1 \* 109/l \* 109/l; platelet \< 25; hb \< 60g/l * hiv test positive

Keywords: anaplastic large cell lymphoma anaplastic lymphoma kinase rearrangement crizotinib chop chemotherapy
hpv vaccine therapy in interrupting progression in patients with high-grade vulvar or anal lesions

Conditions: High Grade Anal Canal Intraepithelial Neoplasia; High Grade Vulvar Squamous Intraepithelial Lesion

Summary: this phase iv trial studies how well human papillomavirus (hpv) vaccine therapy works in interrupting progression in patients with high-grade vulvar or anal lesions. vaccines made from hpv peptides or antigens may help the body build an effective immune response to kill tumor cells and decrease the chance of vulvar or anal lesions to progress or come back.

outline: patients are randomized to 1 of 2 arms. arm i: patients receive recombinant human papillomavirus nonavalent vaccine intramuscularly (im) at baseline, 2 months, and 6 months. arm ii: patients receive placebo im at baseline, 2 months, and 6 months. after completion of study treatment, patients are followed up at months 7, 12, 18, 24, 36, and 42.

Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosis of initial or recurrent anal or vulvar high-grade squamous intraepithelial lesion (ain2/3 or vin2/3) diagnosed on or after 1/1/2014; study pathologist will use p16 staining as needed to rule out low-grade squamous intraepithelial lesion (lsil) disease * \>= 2 months since last therapy for hsil * no clinical evidence of hsil on screening examination; if hsil is suspected, a biopsy will be done to exclude hsil; patients whose screening visit reveals hsil on biopsy, may be re-screened \>= 2 months after therapy * resident in the catchment area of the clinics and willing to attend up to 8 clinic visits for a 36-month period * sexually active women of child-bearing potential must be willing to use effective contraception through month 7 of the study * if human immunodeficiency virus (hiv) positive, receipt of anti-retroviral therapy continuously for at least 6 months prior to enrollment * ability to give informed consent * willingness to sign medical records release form and tissue release form exclusion criteria: * currently pregnant * chemotherapy (current, within the last month, or anticipated in the next 7 months) * prior history of invasive hpv-related anogenital cancer (cervical, vaginal, vulvar, penile, or anal cancer), or oropharyngeal cancer (base of tongue, tonsil); prior cancer at other sites (including most of oral cavity) or larynx are not exclusions * unstable medical condition (e.g., another malignancy requiring treatment, malignant hypertension, poorly controlled diabetes, another cancer except for fully excised non-melanoma skin cancer) * prior hpv vaccination * known allergy or intolerance to lidocaine * currently participating in an interventional research study related to hpv, except the anal cancer hsil outcomes research (anchor) study (nct02135419) * any other condition which, in the opinion of the investigator, may compromise the subject's ability to follow study procedures and safely complete the study
health literacy, physical and cognitive function, health-related behaviors, and quality of life in copd

Conditions: COPD; Health Literacy; Health-Related Behavior

Summary: health literacy is important for controlling disease progression and living a healthy life with illness. high health literacy is associated with higher cognitive performance and lower health-related quality of life. physical, psychological, and social impairments are seen in chronic obstructive pulmonary disease (copd). studies investigating the relationship between health literacy and functional capacity, quality of life, physical activity, cognitive function, health-related behavior, and activities of daily living in individuals with copd are limited. therefore, the aim of this study was to compare individuals with copd with healthy individuals in terms of health literacy, functional capacity, quality of life, physical activity, cognitive function, health-related behavior, and activities of daily living and to investigate the relationship between health literacy and functional capacity, quality of life, physical activity, cognitive function, health-related behavior, and activities of daily living in individuals with copd.


Eligibility criteria:
inclusion criteria for the copd group: * being over 40 years old, * diagnosed with copd and being clinically stable, * being able to cooperate with the tests to be performed, * not having any cardiovascular disease, orthopedic or neurological problems that may affect the tests, * being willing to participate in the study. exclusion criteria for the copd group: * being in an acute exacerbation period, * having any cardiovascular disease, orthopedic or neurological problems that may affect the tests, * not being willing to participate in the study. inclusion criteria for the control group: * being willing to participate in the study and being over 40 years old * not having any known disease exclusion criteria for the control group: * not being able to cooperate with the tests to be performed * not being willing to participate in the study
internet-based cognitive behavioral therapy for individuals with gambling disorder in indonesia

Conditions: Gambling

Summary: gambling disorder (gd) has become a wide concern in indonesia, as many negative consequences aroused from this psychiatric condition. prompt treatment with appropriate method of delivery is required to achieve optimal outcome in gd patients. this study aims to determine the effectiveness and feasibility of internet-based cognitive behavioral therapy (icbt) in treating gd. this non-randomised pilot and feasibility study will recruit 20 people with gd. all participants will receive the icbt intervention through self-learning videos and guided weekly group sessions. the effectiveness of the intervention will be assessed at baseline (week 0), post-treatment completion (week 10), and 6 weeks post-treatment (week 16). expanded access of the icbt module will not be available until after the study completion.


Eligibility criteria:
inclusion criteria: * be aged 18-59 years old; * be screened as probable pathological gambler based on south oaks gambling screen (sogs); * have access to electronic devices (ie, smartphone, mobile tablet, personal computer) with internet connection; * be proficient in indonesian language; * have agreed to take part in the study by filling out the informed consent form. exclusion criteria: * have severe mental disorders or intellectual disabilities; * have extreme agitation that hinder instrument fill out and adequate cognitive behavior therapy participation.
a randomized, open-label study comparing two different rabies vaccine schedules in chinese children and older adults

Conditions: Rabies

Summary: this study was designed to evaluate the safety and immunogenicity of two simulated postexposure rabies vaccination schedules (zagreb 2-1-1 and essen 1-1-1-1-1) in chinese children and older adults.

this study was designed to evaluate the safety and immunogenicity of rabipur zagreb (2-1-1) and rabipur essen (1-1-1-1-1) simulated post exposure vaccination schedules in chinese children and older adults. subjects randomized to group 1 (zagreb) will receive 4 doses of rabies vaccine day 1 (2 doses), and on day 8 and day 22. subjects randomized to group 2 (essen) will receive 5 doses of rabies vaccine on days 1, 4, 8, 15, and 29. first vaccine will be administered on study day 1. 240 children and 400 older adults, a total of 640, is planned to be enrolled into the study. subjects will be divided further into age subsets of equal numbers within each age cohort (children: 6 to 11 years of age and 12 to 17 years of age; older adults: 51 to 60 years of age and 61 years of age and older. within each age subset, subjects will be assigned randomly in a 1:1 ratio. the primary objective is to establish the non-inferiority of the rabipur zagreb (2-1-1) schedule relative to the conventional rabipur essen (1-1-1-1-1) schedule based on geometric mean titers (gmc), and the secondary objective is to assess the percent of subjects with rabies virus neutralizing titer ≥ 0.5 iu/ml 14 days after the first vaccinations (study day 15) for each schedule and age cohort

Eligibility criteria:
inclusion criteria: * individuals between 6-17 years of age and 51 years of age or older * individuals who were in good health * provided consent, complied with study procedures and duration of follow-up exclusion criteria: * contraindications to vaccination with rabies vaccine * body temperature ≥37.5◦c (axillary) within 3 days of intended study vaccination * known hypersensitivity to the components of the vaccine * previously received any rabies vaccine or immune globulin * previous or planned treatment with antimalarial medications * history of psychiatric disease, immune disorder, bleeding disorder, drug/alcohol abuse within the past 2 years, malignancy * female subjects who were pregnant or unwilling to practice acceptable birth control methods * individuals enrolled or plans to enroll in another investigational trial

Keywords: rabies virus, postexposure, vaccine schedule, children, older adults
predicting long-term clinical outcomes in chinese breast cancer patients receiving neoadjuvant chemotherapy

Conditions: Breast Neoplasms

Summary: at present, the majority of studies on neoadjuvant chemotherapy (nac) in patients with breast cancer (bc) use pathological complete response (pcr) as a surrogate marker for patient prognosis, with significant improvements in pcr indicating better long-term survival. however, there is still a lack of non-invasive tools for accurately predicting the prognosis and pcr of bc patients undergoing nac. recent research has introduced emerging artificial intelligence machine learning (ml) and deep learning (dl) algorithms such as bayesian methods, k-nearest neighbors (knn), decision trees, support vector machines (svm), xgboost, resnet, convolutional neural networks, and transformer models, which have brought new avenues of exploration for cancer researchers. the integration of ai with imaging, pathology, genomics, and other multi-omics has non-invasively improved preoperative diagnosis of breast cancer and, when combined with clinical factors, can assess postoperative survival. moreover, current research data is limited, and reliable predictive models require extensive data for training. therefore, establishing a multi-center database is essential.


Eligibility criteria:
inclusion criteria: 1. women with invasive breast cancer who received neoadjuvant chemotherapy (nac) treatment in various hospitals from 2008 to 2019 (follow-up endpoint december 31, 2024) 2. women with primary breast cancer (stage ii-iii) confirmed by pre-nac needle biopsy, along with recorded clinical, pathological, and prognostic information 3. with mr images before the first cycle of nac and before surgery 4. with pathological he staining images, including biopsy pathology and postoperative major pathology exclusion criteria: 1. any form of treatment was received before nac, including endocrine therapy, radiotherapy, and chemotherapy 2. disease metastasis occurred during nac 3. breast cancer patients with secondary malignancies from other cancers 4. patients did not complete surgery and were lost to follow-up
deworming against tuberculosis

Conditions: Tuberculosis

Summary: the purpose of this study is to investigate whether treatment against intestinal helminths in patients with pulmonary tuberculosis undergoing chemotherapy could improve the clinical outcome by enhancing host immunity.

mycobacterium tuberculosis causing tuberculosis (tb) is a major global public health problem. because of increasing multi drug resistance and the long treatment period of at least six months, new therapeutic options are urgently needed. in countries like ethiopia where tb is endemic, chronic worm infection is also highly prevalent. recent data support that helminth infection might limit the host response against tb by inhibition of the th1-response that is crucial in controlling the disease. in this study we want to test the hypothesis that albendazole treatment of patients coinfected with helminths and tb could improve clinical outcome in addition to chemotherapy against tb. additionally we will investigate the immunological interactions between tb and chronic helminths infection.

Eligibility criteria:
inclusion criteria: * informed and written consent to take part in the study * newly diagnosed pulmonary tb patients according to the who definitions of active tuberculosis who have a positive stool sample for helminths other than schistosoma spp. exclusion criteria: * pregnancy * corticosteroid or antibiotic treatment * symptomatic (diarrhoea) infection caused by worm infection * chronic diseases or acute infectious diseases other than tb or hiv * stool sample positive for schistosoma spp

Keywords: deworming tuberculosis tb-score albendazole helminths
neuromuscular stimulation versus intermittent compression for venous thromboembolism prophylaxis in critical care

Conditions: Critical Illness; Sepsis; Acute Illness; Venous Thromboembolism

Summary: in this prospective, randomised, open-label, parallel group, feasibility trial; the investigators will objectively assess whether it is feasible to apply the geko device to critically ill adults for the prevention of venous thromboembolism (vte) compared to usual care with intermittent pneumatic compression devices (ipcs).

vte is a common problem amongst patients in critical care. current measures include intermittent pneumatic compression devices, used to aid the venous return of blood from the lower limbs. these devices are contraindicated and/or poorly tolerated by some patients. neuromuscular stimulation of the lower leg muscles might offer a better tolerated and more physiological alternative to ipcs. in this feasibility trial the investigators will randomly allocate 40 patients to receive either the geko device (n=20) or ipcs (n=20) as principal means of mechanical vte prophylaxis.

Eligibility criteria:
inclusion criteria: * male or female aged ≥ 18 years. * intact healthy skin at the proposed site of gekotm device application. * within 24 hours of their admission to critical care * expected to remain in critical care until the day after tomorrow exclusion criteria: * use of any concurrent neuro-modulation drug or device (e.g. neuromuscular blocking agents). * trauma to the lower limbs that would prevent geko™ from stimulating the common peroneal nerve. * inability to palpate the fibula head in order to apply geko device effectively * inability to obtain valid written consent from the participant or their designated legal representative

Keywords: venous thromboembolism critical illness
dose-finding study of glpg0634 as monotherapy in active rheumatoid arthritis (ra) participants (darwin2)

Conditions: Rheumatoid Arthritis

Summary: * participants suffering from active rheumatoid arthritis who had an inadequate response to methotrexate were evaluated for improvement of disease activity (efficacy) when taking glpg0634 as monotherapy (3 different doses - 50 milligram (mg), 100 mg and 200 mg once daily) or matching placebo for 24 weeks. * during the course of the study, patients were also examined for any side effects that could occur (safety and tolerability), and the amount of glpg0634 present in the blood (pharmacokinetics) as well as the effects of glpg0634 on disease- and mechanism of action-related parameters in the blood (pharmacodynamics) were determined. also, the effects of different doses of glpg0634 administration on participants' disability, fatigue and quality of life were evaluated.

* treatment duration was 24 weeks in total. * however, at week 12, all participants on placebo and the participants on the 50 mg dose who had not achieved 20% improvement in swollen joint count (sjc66) and tender joint count (tjc68) were assigned (automatically via interactive web response system (iwrs)) to 100 mg once daily (qd) in a blinded fashion and continued treatment until week 24. * participants in the other groups maintained their randomized treatment until week 24.

Eligibility criteria:
inclusion criteria: * male or female subjects who are ≥18 years of age on the day of signing informed consent, * have a diagnosis of ra since at least 6 months and meeting the 2010 acr/eular criteria of ra and acr functional class i-iii, * have ≥6 swollen joints (from a 66-joint count) and ≥8 tender joints (from a 68-joint count) at screening and at baseline, * screening serum c-reactive protein ≥ 0.7 x upper limit of laboratory normal range (uln), * have shown an inadequate response in terms of either lack of efficacy or toxicity to mtx, * have agreed to be washed out from mtx for a period of at least 4 weeks before or during the screening period. exclusion criteria: * current therapy with any non-biological disease modifying anti-rheumatic drug (dmard), with the exception of antimalarials, which must be at a stable dose for at least 12 weeks prior to screening, * current or previous ra treatment with a biologic dmard, with the exception of biologic dmards: administered in a single clinical study setting, and; more than 6 months prior to screening (12 months for rituximab or other b cell depleting agents), and; where the biologic dmard was effective, and if discontinued, this should not be due to lack of efficacy, * previous treatment at any time with a cytotoxic agent, other than mtx, before screening.